Literature DB >> 25233818

Incidence of deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy with a latanoprost ophthalmic solution.

R Sakata1, S Shirato2, K Miyata3, M Aihara4.   

Abstract

PURPOSE: Among some local side effects of prostaglandin-associated periorbitopathy (PAP), deepening of the upper eyelid sulcus (DUES) is the most prominent clinical feature, and is one of the most significant adverse cosmetic events. Here, we prospectively investigated the incidence of DUES in Japanese open-angle glaucoma patients initially treated with latanoprost (Xalatan 0.005%) ophthalmic solution.
METHODS: This was an open-label prospective study. Facial photographs and subjective reports of the recognition of DUES were obtained at the beginning of latanoprost treatment and at 2, 4, and 6 months thereafter. Intraocular pressure (IOP) was measured at three consecutive visits before and after treatment with latanoprost. The incidence of DUES was evaluated objectively by three blinded investigators who compared the series of photographs.
RESULTS: A total of 52 eyes of 52 newly diagnosed open-angle glaucoma Japanese patients (28 males, 24 females) were evaluated. The objective rate of DUES was 1/52 (2%; 95% CI 0.05 to 10.7%) at 2 months, 2/52 (4%; 95% CI 0.5 to 13.9%) at 4 months, and 3/52 (6%; 95% CI 1.2 to 16.9%) at 6 months. During this period, no patient self-reported an occurrence of DUES. Mean IOPs before and after treatment were 16.5±2.9 and 13.8±3.0 mm Hg, respectively. Latanoprost reduced the IOP significantly (P<0.0001, paired t-test).
CONCLUSIONS: Latanoprost caused DUES rarely and had a robust IOP-lowering effect in Japanese glaucoma patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25233818      PMCID: PMC4268464          DOI: 10.1038/eye.2014.224

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  27 in total

1.  Incidence of deepening of the upper eyelid sulcus after switching from latanoprost to bimatoprost.

Authors:  Makoto Aihara; Shiroaki Shirato; Rei Sakata
Journal:  Jpn J Ophthalmol       Date:  2011-09-28       Impact factor: 2.447

Review 2.  From PGF(2alpha)-isopropyl ester to latanoprost: a review of the development of xalatan: the Proctor Lecture.

Authors:  J W Stjernschantz
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-05       Impact factor: 4.799

Review 3.  Side effects associated with prostaglandin analog therapy.

Authors:  Albert Alm; Ian Grierson; M Bruce Shields
Journal:  Surv Ophthalmol       Date:  2008-11       Impact factor: 6.048

4.  Periorbital changes associated with topical bimatoprost.

Authors:  Theodoros Filippopoulos; Jayter S Paula; Nurhan Torun; Mark P Hatton; Louis R Pasquale; Cynthia L Grosskreutz
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2008 Jul-Aug       Impact factor: 1.746

Review 5.  Recovery of orbital fat pad prolapsus and deepening of the lid sulcus from topical bimatoprost therapy: 2 case reports and review of the literature.

Authors:  Sayime Aydin; Işil Işikligil; Yasemin Aktan Tekşen; Erkin Kir
Journal:  Cutan Ocul Toxicol       Date:  2010-09       Impact factor: 1.820

6.  Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs.

Authors:  Kenji Inoue; Minako Shiokawa; Masato Wakakura; Goji Tomita
Journal:  J Glaucoma       Date:  2013 Oct-Nov       Impact factor: 2.503

7.  Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost.

Authors:  Juwan Park; Hyun Kyung Cho; Jung-Il Moon
Journal:  Jpn J Ophthalmol       Date:  2011-02-18       Impact factor: 2.447

8.  [Orbital fat atrophy in glaucoma patients treated with topical bimatoprost--can bimatoprost cause enophthalmos?].

Authors:  C Tappeiner; B Perren; M E Iliev; B E Frueh; D Goldblum
Journal:  Klin Monbl Augenheilkd       Date:  2008-05       Impact factor: 0.700

9.  Incidence of deepening of the upper eyelid sulcus after topical use of travoprost ophthalmic solution in Japanese.

Authors:  Katsuhiko Maruyama; Shiroaki Shirato; Asako Tsuchisaka
Journal:  J Glaucoma       Date:  2014-03       Impact factor: 2.503

10.  Incidence of deepening of upper eyelid sulcus after topical use of tafluprost ophthalmic solution in Japanese patients.

Authors:  Katsuhiko Maruyama; Asako Tsuchisaka; Jumpei Sakamoto; Shiroaki Shirato; Hiroshi Goto
Journal:  Clin Ophthalmol       Date:  2013-07-15
View more
  6 in total

1.  Prostaglandin-associated periorbitopathy.

Authors:  Neha Shrirao; Mona Khurana; Bipasha Mukherjee
Journal:  Indian J Ophthalmol       Date:  2016-06       Impact factor: 1.848

2.  Effects of the Selective EP2 Receptor Agonist Omidenepag on Adipocyte Differentiation in 3T3-L1 Cells.

Authors:  Yasuko Yamamoto; Takazumi Taniguchi; Tomoaki Inazumi; Ryo Iwamura; Kenji Yoneda; Noriko Odani-Kawabata; Takeshi Matsugi; Yukihiko Sugimoto; Naveed K Shams
Journal:  J Ocul Pharmacol Ther       Date:  2020-01-14       Impact factor: 2.671

3.  Prostaglandin F2α Agonists Negatively Modulate the Size of 3D Organoids from Primary Human Orbital Fibroblasts.

Authors:  Kaku Itoh; Fumihito Hikage; Yosuke Ida; Hiroshi Ohguro
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-06-03       Impact factor: 4.799

4.  Shortening of interpupillary distance after topical prostaglandin analog eye drop application in an ophthalmic surgeon: A case report.

Authors:  Ichiya Sano; Hidenori Takahashi; Takeshi Hara; Hidetoshi Kawashima; Chihiro Mayama
Journal:  Am J Ophthalmol Case Rep       Date:  2022-03-15

5.  Effects of pre-surgical administration of prostaglandin analogs on the outcome of trabeculectomy.

Authors:  Takako Miki; Tomoko Naito; Miyuki Fujiwara; Ryoichi Araki; Rieko Kiyoi; Yusuke Shiode; Atsushi Fujiwara; Yuki Morizane; Fumio Shiraga
Journal:  PLoS One       Date:  2017-07-20       Impact factor: 3.240

6.  Prostaglandin F2 and EP2 Agonists Exert Different Effects on 3D 3T3-L1 Spheroids during Their Culture Phase.

Authors:  Yosuke Ida; Masato Furuhashi; Megumi Watanabe; Araya Umetsu; Fumihito Hikage; Hiroshi Ohguro
Journal:  Biomedicines       Date:  2021-12-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.